Welcome to our dedicated page for Becton Dickinson & Co SEC filings (Ticker: BDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Becton, Dickinson and Company (BD) SEC filings page for ticker BDX provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a New Jersey–incorporated issuer with common stock listed on the New York Stock Exchange, BD files current reports on Form 8-K, annual and quarterly reports, proxy statements and other documents that give investors insight into its financial condition, governance and capital structure.
BD’s recent Form 8-K filings include disclosures on financial results, such as preliminary unaudited revenue and quarterly earnings press releases, as well as corporate events like executive transitions, board appointments and changes in credit facilities. For example, BD has reported the appointment of new directors, the planned transition of its chief financial officer role, and the execution of a third amended and restated revolving credit agreement that provides senior unsecured financing for general corporate purposes. Other 8-K filings describe temporary blackout periods under the BD 401(k) Plan related to a transaction involving Waters Corporation.
Investors can also review BD’s definitive proxy statement on Schedule 14A, which outlines matters for shareholder voting, board composition, executive compensation programs and strategic themes such as the BD2025 and Excellence Unleashed strategies. Debt-related filings, including listings of various series of notes and a Form 25 relating to the removal from listing of 0.034% Notes due 2025, help users understand BD’s capital markets activities. Common stock and several note issues remain registered and listed on the NYSE, as indicated in the filings.
On this page, Stock Titan presents BD’s SEC filings alongside AI-powered summaries that highlight key points from lengthy documents, such as 10-K and 10-Q reports, 8-K event descriptions and proxy materials. Users can quickly identify information about BD’s revolving credit facilities, leverage covenants, executive changes, shareholder meetings and note listings, while still having the option to review the full original filings from EDGAR for detailed analysis.
Becton, Dickinson and Company insider plans small stock sale under Rule 144. A person identified as Michael Feld has filed a notice to sell 74 shares of the company’s common stock through a broker on the NYSE, with an aggregate market value of approximately
The filing also lists prior sales over the past three months under a Rule 10b5-1 trading plan, including 75 shares sold on
Becton Dickinson & Co. executive Michael Feld, who serves as EVP, CRO and President of Life Sciences, reported a small stock sale. On 12/26/2025, he sold 74 shares of Becton Dickinson common stock at a price of $196.08 per share. After this transaction, he beneficially owned 16,506 shares directly.
The filing notes that this transaction was carried out under a Rule 10b5-1 trading plan that Feld adopted on February 7, 2025. Such plans allow insiders to pre-arrange trades according to set instructions, helping separate their personal trading activity from the timing of any nonpublic information they may hold.
Becton, Dickinson and Company is asking shareholders to vote at its virtual 2026 annual meeting on four items: electing 13 directors, ratifying Ernst & Young as independent auditor, approving named executive officer pay on an advisory basis, and increasing the shares available under its 2004 equity-based compensation plan by 3,935,000 shares.
The materials highlight record fiscal 2025 revenue of $21.8 billion, GAAP EPS of $5.82 and record adjusted diluted EPS of $14.40, supported by margin expansion from its BD Excellence program. BD returned $2.2 billion to shareholders through buybacks and dividends and marked its 54th consecutive annual dividend increase.
BD also describes the planned Reverse Morris Trust transaction combining its Biosciences and Diagnostic Solutions businesses with Waters Corporation, which is expected to generate about $4 billion in cash for BD and give its shareholders roughly 39% ownership of the new life sciences company, alongside extensive detail on governance, sustainability goals and risk oversight.
Becton Dickinson & Co executive Michael David Garrison reported selling 629 shares of common stock at $196.03 per share on December 17, 2025. After this sale, he directly owns 13,105 shares.
Garrison serves as EVP & Pres Med.Essntl&BioPharm, and the sale was made under a Rule 10b5-1 plan he adopted on August 13, 2025.
A shareholder of BDX has filed a notice under Rule 144 to sell 629 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate sale date of 12/17/2025. The planned sale has an aggregate market value of $123,529.31, compared with 285,418,551 shares of the same class reported as outstanding.
The shares to be sold were acquired on 11/26/2025 as Restricted Stock Units from the issuer, in an amount of 629 units, with the same date listed as the date of payment and the nature of payment noted as "N/A." By signing the notice, the seller represents that they do not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.
Becton Dickinson & Co. reported the equity holdings of its interim CFO, Vitor Roque, as of 12/05/2025. He beneficially owns 4,477 shares of common stock, which includes shares held directly and restricted stock units granted under the company’s 2004 Employee and Director Equity-Based Compensation Plan.
Roque also holds multiple grants of stock appreciation rights covering various amounts of common stock, with grant dates from 11/26/2018 through 11/26/2025, exercise prices ranging from $222.60 to $251.06, and expiration dates between 11/26/2027 and 11/26/2034. These rights vest in four annual installments beginning one year from each grant date and are held directly. A power of attorney authorizing Donna Kalazdy to sign on Roque’s behalf is also referenced.
Becton Dickinson & Co. executive Michael Feld, who serves as EVP, CRO & President of Life Sciences, reported a small sale of company stock. On 12/01/2025, he sold 75 shares of Becton Dickinson common stock at a price of $193.36 per share. After this transaction, he beneficially owned 16,580 shares of Becton Dickinson common stock in direct ownership. The filing notes that this sale was made under a pre-arranged Rule 10b5-1 trading plan that Feld adopted on February 7, 2025, which is designed to allow insiders to sell shares according to a preset schedule.
Becton, Dickinson and Company reported an insider equity award for director Jacqueline Wright. On 12/01/2025, she acquired 180 shares of common stock through a grant of restricted stock units under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. The Form 4 shows the transaction as an acquisition at a stated price of $0, reflecting a stock-based compensation award rather than an open-market purchase. Following this grant, she beneficially owned 180 shares, held directly.
Becton, Dickinson and Company director reports stock award. A company director filed a Form 4 reporting the acquisition of 180 shares of Becton Dickinson common stock on 12/01/2025. The filing shows the transaction code "A," indicating an acquisition, at a price of $0 per share, and lists 180 shares beneficially owned directly after the transaction.
The footnote explains that these 180 shares represent restricted stock units granted under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. This reflects routine equity-based compensation rather than an open-market purchase or sale.
FAQ
What is the current stock price of Becton Dickinson & Co (BDX)?
What is the market cap of Becton Dickinson & Co (BDX)?
